Shin Dong Geum, Han Soo Min, Kim Doo Il, Rhee Moo-Yong, Lee Byoung-Kwon, Ahn Young Keun, Cho Byung Ryul, Woo Jeong-Taek, Hur Seung-Ho, Jeong Jin-Ok, Jang Yangsoo, Lee Ji Hyun, Lee Sang-Hak
Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Department of Pharmacology, Pharmacogenomic Research Center for Membrane Transporters, Brain Korea 21 PLUS Project for Medical Sciences, Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.
Atherosclerosis. 2015 Nov;243(1):53-8. doi: 10.1016/j.atherosclerosis.2015.08.033. Epub 2015 Sep 5.
Proper screening and diagnosis of familial hypercholesterolemia (FH) is of critical importance for cardiovascular prevention. However, the clinical diagnosis of FH remains difficult partly because its phenotype can vary between different ethnicities. The aim of this study was to determine the clinical features and the best diagnostic approach in Korean FH patients. The predictors of putative pathogenic mutations and coronary artery disease (CAD) were also identified.
Ninety-seven patients with low-density lipoprotein-cholesterol >190 mg/dL and xanthoma or FH-compatible family history were included. Putative pathogenic mutations in LDLR, APOB, or PCSK9 genes were identified in 32% of the enrolled patients. The subjects were classified according to four sets of clinical criteria (Simon Broome, Dutch, MEDPED, Japanese). The mutation rates in definite type FH of Simon Broome or Dutch criteria were 35%-37% and lower in our patients than in those of other countries. The mutation detection rate by MEDPED criteria was 67%-75% and higher than those based on other criteria. The best low-density lipoprotein-cholesterol (LDL-C) threshold for predicting mutations was 225 mg/dL. LDL-C was found to be the only independent predictor of mutation carriers, while hypertension and low high-density lipoprotein-cholesterol were predictive of CAD.
The conventional clinical criteria showed limited mutation detection power and low specificities in Korean FH patients, in whom the best LDL-C threshold for putative mutation was 225 mg/dL. Traditional cardiovascular risk factors were also significantly associated with CAD risk in this population.
家族性高胆固醇血症(FH)的正确筛查和诊断对于心血管疾病的预防至关重要。然而,FH的临床诊断仍然困难,部分原因是其表型在不同种族之间存在差异。本研究的目的是确定韩国FH患者的临床特征和最佳诊断方法。还确定了推定致病突变和冠状动脉疾病(CAD)的预测因素。
纳入了97例低密度脂蛋白胆固醇>190mg/dL且有黄色瘤或FH相关家族史的患者。在32%的入选患者中鉴定出LDLR、APOB或PCSK9基因的推定致病突变。根据四套临床标准(西蒙·布鲁姆、荷兰、MEDPED、日本)对受试者进行分类。西蒙·布鲁姆或荷兰标准确定型FH的突变率在我们的患者中为35%-37%,低于其他国家的患者。MEDPED标准的突变检测率为67%-75%,高于其他标准。预测突变的最佳低密度脂蛋白胆固醇(LDL-C)阈值为225mg/dL。发现LDL-C是突变携带者的唯一独立预测因素,而高血压和低高密度脂蛋白胆固醇是CAD的预测因素。
传统临床标准在韩国FH患者中的突变检测能力有限且特异性较低,其中推定突变的最佳LDL-C阈值为225mg/dL。在该人群中,传统心血管危险因素也与CAD风险显著相关。